AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACL - AUSTRALIAN CLINICAL LABS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.77
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.55

18 Mar
2024

-0.010

OPEN

$2.56

-0.39%

HIGH

$2.59

299,488

LOW

$2.53

TARGET
$3.133 22.9% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
ACL: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 15.4 xxx
DPS (cps) xxx N/A 8.3 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 16.5 xxx
Dividend Yield xxx N/A 3.3% xxx
Div Pay Ratio(%) xxx N/A 54.0% xxx

Dividend yield today if purchased 3 years ago: 1,400.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

5.49

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 14/09 - ex-div 7c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 20192020202120222023
EPS Basic xxxxxxxxxxxx17.9
DPS All xxxxxxxxxxxx14.0
Sales/Revenue xxxxxxxxxxxx692.1 M
Book Value Per Share xxxxxxxxxxxx86.0
Net Operating Cash Flow xxxxxxxxxxxx143.7 M
Net Profit Margin xxxxxxxxxxxx5.19 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20192020202120222023
Return on Capital Employed xxxxxxxxxxxx17.73 %
Return on Invested Capital xxxxxxxxxxxx9.12 %
Return on Assets xxxxxxxxxxxx5.95 %
Return on Equity xxxxxxxxxxxx17.73 %
Return on Total Capital xxxxxxxxxxxx11.40 %
Free Cash Flow ex dividends xxxxxxxxxxxx39.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20192020202120222023
Short-Term Debt xxxxxxxxxxxx101 M
Long Term Debt xxxxxxxxxxxx215 M
Total Debt xxxxxxxxxxxx316 M
Goodwill - Gross xxxxxxxxxxxx159 M
Cash & Equivalents - Generic xxxxxxxxxxxx21 M
Price To Book Value xxxxxxxxxxxx4.00

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20192020202120222023
Capex xxxxxxxxxxxx6.9 M
Capex % of Sales xxxxxxxxxxxx1.00 %
Cost of Goods Sold xxxxxxxxxxxx546 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx90 M
Research & Development xxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

29/02/2024

3

Neutral

$2.55

0%

Australian Clinical Labs posted first half revenue in line with expectation but higher opex led to a -33% miss on profit, Macquarie reports. FY24 earnings guidance has been cut by -8% and implies a 62.5% skew to the second half. The broker has cut its forecast to the lower end of the range.

The second half had started well, with underlying earnings up 204% year on year, but this growth rate has "materially moderated into February".

While Macquarie expects a recovery in pathology over the medium-longer term, subdued GP volumes are a near-term constraint. A
significant second half skew is required to meet the guidance provided.

The broker awaits signs of a recovery in GP consultations before becoming more positive. Neutral retained.

Target falls to $2.55 from $3.20.

FORECAST
Macquarie forecasts a full year FY24 dividend of 9.00 cents and EPS of 15.40 cents.
Macquarie forecasts a full year FY25 dividend of 11.00 cents and EPS of 19.70 cents.

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

ACL STOCK CHART